We investigated if the magnitude of the Type 2 diabetes (T2D)-induced impairments in peak oxygen uptake (V O2) and V O2 kinetics was affected by menopausal status. Twenty-two women with T2D (8 premenopausal, 14 postmenopausal), and 22 nondiabetic (ND) women (11 premenopausal, 11 postmenopausal) matched by age (range ϭ 30 -59 yr) were recruited. Participants completed four bouts of constant-load cycling at 80% of their ventilatory threshold for the determination of V O2 kinetics. Cardiac output (CO) (inert gas rebreathing) was recorded at rest and at 30 s and 240 s during two additional bouts. Peak V O2 was significantly (P Ͻ 0.05) reduced in both groups with T2D compared with ND counterparts (premenopausal, 1.79 Ϯ 0.16 vs. 1.55 Ϯ 0.32 l/min; postmenopausal, 1.60 Ϯ 0.30 vs. 1.45 Ϯ 0.24 l/min). The time constant of phase II of the V O2 response was slowed (P Ͻ 0.05) in both groups with T2D compared with healthy counterparts (premenopausal, 29.1 Ϯ 11.2 vs. 43.0 Ϯ 12.2 s; postmenopausal, 33.0 Ϯ 9.1 vs. 41.8 Ϯ 17.7 s). At rest and during submaximal exercise absolute CO responses were lower, but the "gains" in CO larger (both P Ͻ 0.05) in both groups with T2D. Our results suggest that the magnitude of T2D-induced impairments in peak V O2 and V O2 kinetics is not affected by menopausal status in participants younger than 60 yr of age.
IT IS WELL ESTABLISHED that endogenous estrogen confers a cardioprotective effect in healthy premenopausal women compared with age-similar men and postmenopausal women (19, 40) . After menopause, however, women have a marked increase in the incidence of cardiovascular disease (CVD) (3, 25) with this risk increasing to levels similar to those in men (5, 34) . On the other hand, the greater cardioprotective effects and lower likelihood of developing CVD observed in healthy premenopausal women compared with men are tempered by the presence of Type 2 diabetes (T2D), so that the risk of CVD is similar between premenopausal women and age-similar men with T2D (12, 31) .
The enhanced endothelium-dependent vascular function referred to as the "female advantage" (34, 44) is one of the cardioprotective effects of estrogen in healthy premenopausal women which is tempered by the presence of T2D (44) . Thus it would be reasonable to think that T2D impairs the vasodilatory function and possibly oxygen delivery and exercise tolerance in premenopausal women to a greater extent than in age-similar men or postmenopausal women. This would suggest that the sex-specific influence of T2D on exercise tolerance would be more pronounced between premenopausal women and age-similar men (i.e., greater exercise intolerance in women with and without T2D than in men) than among postmenopausal women and their age-similar counterparts.
In fact, Regensteiner et al. (36) have recently reported that the differences in the magnitude of the T2D-induced impairments in peak oxygen uptake (V O 2 ) are significantly larger between premenopausal women with T2D and healthy controls than between men with and without T2D of similar ages although no differences in V O 2 kinetics at moderate submaximal intensities due to T2D or sex were observed (36) . In contrast, O'Connor et al. (33) showed that these sex-specific differences were not apparent in middle-aged participants (where the majority of women were postmenopausal) as the T2D-induced significant reductions in peak V O 2 and V O 2 kinetics were similar between men and women with T2D compared with nondiabetic counterparts (33) . However, it should be noted that study participants with T2D of O'Connor et al. (33) had been diagnosed with T2D for longer than participants in the study of Regensteiner et al. (36) (mean time since diagnosis ϭ ϳ5 vs. ϳ3 yr, respectively) and a larger proportion of them were taking diabetes medications (ϳ70% vs. ϳ35%, respectively), suggesting potential additional cardiovascular abnormalities. In addition, the inclusion of some study participants older than 60 yr of age in the study by O'Connor et al. (33) may have affected the outcomes given that the diabetes-induced impairments in exercise performance appear to be masked by older age (between 60 and 70 yr) at least in men (32, 47) . Thus it is relevant to investigate if the T2D-induced impairments in exercise performance are affected by menopausal status while participants with T2D are matched by time since diagnosis and disease severity and older study participants (Ͼ 60 yr) are excluded.
The main aim of the present study was to explore the menopause-dependent influence on the T2D-induced impairments on peak exercise performance during a graded exercise and V O 2 kinetics during submaximal exercise. Subordinate aims of the study were to test the effect of menopause in healthy women on these outcomes. We hypothesized that the magnitude of the T2D-induced reduction in peak V O 2 responses during a graded cycling exercise would be larger among premenopausal women than in postmenopausal women, due to a larger influence of menopause on peak performance in healthy women. We also hypothesized that menopausal status would not influence the T2D-induced effects on V O 2 kinetics during submaximal cycling. To explore the mechanistic basis of any menopausal status-specific effects in V O 2 kinetics the rates of changes in cardiac output (CO), heart rate (HR), and stroke volume (SV) during submaximal cycling exercise were also assessed.
METHODS

Subjects
Forty-four women took part in this study. Twenty-two of the participants were being treated for Type 2 diabetes (8 premenopausal, 14 postmenopausal) and 22 were sex-and body mass index (BMI)-matched healthy controls (11 premenopausal, 11 postmenopausal) ( Table 1 ). The time since diagnosis of diabetes (means Ϯ SD) for premenopausal participants was 4.3 Ϯ 2.2 yr and for postmenopausal participants 5.0 Ϯ 3.3 yr. To avoid the effects of age previously established in men (see above; 32, 47) we limited the age of postmenopausal women to Ͻ60 yr, so that all premenopausal women were between the ages of 30 and 46 yr, whereas all postmenopausal women were between the ages of 46 and 59 yr. Women were premenopausal based upon regular menstrual cycles. Subjects with type 2 diabetes were recruited from the Diabetes Day Care centers at St. Columcille's and St, Vincent's University Hospitals, Dublin, following a chart review. Subjects with T2D were treated by diet (n ϭ 7) or oral hypoglycemic agents (metformin monotherapy, n ϭ 12; metformin and sulfonylurea, n ϭ 3) and at the start of this study displayed no clinical evidence of ischemic heart disease (normal electrocardiogram, ECG, during treadmill stress test), peripheral arterial disease (0.9 Ͻ Ankle-Brachial Index, ABI, Ͻ 1.3), kidney dysfunction (consistent urinary protein Ͼ 200 mg/dl) or liver dysfunction (urinary creatinine levels Ͼ 2.2 mg/dl). Controlled hypertensives were admitted to the study but participants taking ␤-blockers were excluded. All subjects were sedentary (Ͻ1 h/wk of moderate-intensity exercise) for the previous 6 mo, as confirmed by the Low Level Physical Activity Recall (LOPAR) (37) ( Table 1 ). All subjects provided written informed consent prior to participation, and the study was approved by the Faculty of Health Science Research Ethics Committee and conducted in accordance with the Declaration of Helsinki (2008).
Study Protocol
In an initial visit to the laboratory participants performed a forearm reactive hyperemia protocol in the supine position by venous occlusion strain-gauge plethysmography (Hokanson EC-6), using calibrated mercury-in-Silastic strain gauges as shown elsewhere (14) . This test was performed to explore whether vascular dysfunction in T2D was present in the upper limb. Peak forearm blood flow (FBF, ml·100 ml Ϫ1 ·min Ϫ1 ) and forearm vascular conductance (FVC, ml·100 ml Ϫ1 ·min Ϫ1 ·mmHg Ϫ1 ) measurements recorded at the start of the postocclusion hyperemic response were compared.
Exercise testing. The full exercise testing protocol has been previously performed and is fully described elsewhere (33) . Briefly, each subject was tested on two occasions, separated by 72 h, and at the same time of day. For all premenopausal women testing dates were scheduled to occur during the midfollicular phase of their menstrual cycle (days [5] [6] [7] [8] [9] [10] [11] [12] . Subjects refrained from consuming caffeine and alcohol in the 24 h prior to testing and limited their exercise to normal activities of daily living. All exercise testing was performed on an electrically braked cycle ergometer (Excalibur Sport, Lode, Groningen, Netherlands).
On exercise testing day 1, subjects completed a graded cycling exercise test to failure to determine the first ventilatory threshold (VT) and peak V O2. After a 3-min period of seated rest, all subjects began the graded test by cycling at an initial power output of 40 W for 3 min using a fixed cadence (60 rpm). Thereafter, the power output was increased by 20 W every 3 min until the required cadence could not be maintained (i.e., task failure) (9) . The VT was determined using the V-slope method by identifying the power output at which a clear steeper increase of CO 2 output (V CO2) compared with V O2 occurs (1, 7), peak V O2 was the highest 30-s mean V O2 value recorded before the subject's volitional termination of the test, and peak workload was the highest workload sustained for at least 1 min. On testing day 2, subjects performed six, 6-min bouts of cycling at 80% VT, with each bout separated by 12 min of rest and preceded by a 3-min cycling period at 10 W. V O2 and heart rate (HR) were recorded during the first four bouts, and CO was measured during the last two bouts. The resting periods applied between bouts were sufficient for HR (n ϭ 44) and blood lactate (measured in a subgroup of n ϭ 20) to return to baseline levels. V O2 kinetics parameter estimates have been shown to be similar when calculated from repeated trials performed on the same day or on separate days (42) .
Measurements
During exercise subjects wore a facemask to continuously collect expired air using an online metabolic system (Innocor, Innovision A/S, Odense, Denmark) that measured airflow using a pressure difference pneumotach. Carbon dioxide analysis was performed by using a photoacoustic gas analyzer and oxygen was analyzed using an oxygen sensor (Oxigraf) based on the principle of laser diode absorption spectroscopy. The volume was calibrated with a 3-liter syringe, and the oxygen sensor was calibrated (against room air) prior to each test by the researcher. Both the oxygen sensor and photoacoustic gas analyzer require multipoint calibration performed by the manufacturer periodically (6 -12 mo). Analysis of expired air allowed determination of pulmonary O 2 uptake (V O2), V CO2, minute ventilation (V E), and the respiratory exchange ratio (RER) breath by breath. CO was measured using the same system by the inert gas (sulfur hexafluoride and nitrous oxide) rebreathing technique at rest, 30 s, and 240 s (11, 21) , HR was recorded every 5 s (S610i, Polar Electro Oy, Finland), and stroke volume (SV ϭ CO/HR) and arteriovenous O 2 difference (a-vO2 ϭ V O2/CO) were estimated from these measurements. Final values for all variables were averaged from responses during the final two submaximal exercise bouts.
Data Analysis
To determine the kinetic parameters of V O2 at 80% VT, V O2 responses during the first four bouts were linearly interpolated to 1-s intervals, time aligned and averaged and finally smoothed using a 5-s moving average filter (13) While when exercising below the VT the third phase of the V O2 response results in a steady state (as was the case in 35 of the study participants), 9 subjects revealed a further increase (i.e., an apparent oxygen uptake "slow" component), suggesting that the ventilatory threshold was overestimated in these participants. Thus these data were fitted to either a biexponential function (Eq. 1) or triexponential function (Eq. 2) as follows:
Either one or the other function was selected for fitting on the basis of comparing the goodness-of-fit of these functions (26) and only parameter estimates representing the first two phases ("cardiodynamic" and "primary" phase) are presented. The presence of a third or slow phase in 9 subjects (premenopausal ND, n ϭ 1; postmenopausal ND, n ϭ 3; premenopausal with T2D, n ϭ 1; postmenopausal with T2D, n ϭ 4) has minimal impact on the interpretation of our data since parameters related to the primary phase are unaffected by the presence of the third phase (46) and the outcomes of statistical analyses were unaffected by excluding these subjects. In these equations, baseline V O2 is oxygen uptake during cycling at 10 W, and A c, Ap, and As, c, p, and s, and TDc, TDp, and TDs are the amplitudes, time constants, and time delays of the cardiodynamic, primary and slow components, respectively. The conditional expressions (U c, Up, and Us) limit the fitting of a particular phase to the period at and beyond the time delay associated with that phase. Fitting the cardiodynamic phase allowed us to visually determine the transition between the cardiodynamic and primary phase given the large variation observed in the duration of the cardiodynamic phase (range TD 2-TD1 ϭ 13-48 s). However, the cardiodynamic phase cannot be always described by an exponential term (17) , and thus only its mean duration is presented.
The V O2 data were fitted to either function (Eqs. 1 or 2) using a weighted least-squares nonlinear regression procedure (TableCurve 2D, Systat). Data points lying outside the 95% prediction interval during the initial fit of a model were excluded. The end-exercise V O2 response, referred to as End A, was calculated as the averaged V O2 over the last 30 s of exercise. The functional "gain" of the V O2 response (excluding the slow component) was calculated as follows: [(End A Ϫ As) Ϫ baseline V O2]/(workload at 80% VT Ϫ 10 W). However, the gains for the cardiovascular variables recorded in the constant load bouts 5 and 6 (CO, SV, and HR) as well as the associated a-vO 2 responses were calculated as follows: (responses at 240 s Ϫ responses at rest)/ workload at 80% VT. This was due to the fact that these cardiovascular responses were not recorded during the 3-min cycling periods at 10 W (i.e., baseline cycling).
To assess the dynamic response of CO, the rate of increase of CO over the initial compared with steady-state period of exercise was estimated as the relative or percentage change in CO from baseline (%⌬CO) at 30 s compared with 240 s (%⌬CO ϭ ⌬CO 30/⌬CO240 ϫ 100) (33) .
Statistical Analysis
Physical characteristics and activity levels, peak physiological responses, and kinetic parameters were compared using a two-way (diabetic status vs. menopausal status) ANOVA (PRISM, Version 5.03, GraphPad Software). Cardiovascular responses were assessed using a three-way (diabetic status vs. menopausal status vs. time of measurement) repeated-measures ANOVA (Datadesk Version 6.2.1 OS X, Data Description). Differences between groups were detected using Bonferroni's post hoc test. Significance was set at P Ͻ 0.05. All values are expressed as means Ϯ SD.
RESULTS
Physical Characteristics and Activity Levels
There were no significant differences in BMI or activity levels between groups. Premenopausal women were significantly younger than postmenopausal participants. HbA 1c and fasting glucose levels were significantly higher for individuals with T2D than controls but similar between the two groups with T2D. Peak forearm blood flow and forearm vascular conductance responses were not significantly different among groups (main effect ϭ diabetes status, P ϭ 0.49 for FBF and P ϭ 0.12 for FVC).
Graded Test
Peak V O 2 (l/min and ml·kg Ϫ1 ·min Ϫ1 ) were significantly lower in both groups with T2D compared with their respective nondiabetic counterparts ( Table 2 ). The magnitude of the reduction in relative peak V O 2 (ml·kg Ϫ1 ·min Ϫ1 ) was numerically higher among premenopausal women (ϳ25%) than among postmenopausal women (ϳ8%) (diabetes status ϫ menopausal status interaction, P ϭ 0.11) whereas this magnitude was similar (ϳ13% among premenopausal groups and ϳ9% among postmenopausal groups) when absolute values (l/min) were analyzed (diabetes status ϫ menopausal status interaction, P ϭ 0.57). Peak HR responses were significantly (P Ͻ 0.05) lower in premenopausal women with T2D than controls. This was influenced at least in part by the fact that nondiabetic premenopausal controls were numerically younger and they reached higher mean age-predicted peak HR levels (ϳ100%, range ϭ 98 -102%) than premenopausal women with T2D (ϳ90%, range ϭ 83-102%, where 5 of 8 participants reached an age-predicted peak HR value Ͼ 90%). Importantly, RER responses were similar among the four groups suggesting comparable peak exercise effort. All but one woman in each group reached peak RER values Ն 1.1.
V O 2 Kinetics
V O 2 responses during moderate exercise for representative individuals are presented in Fig. 1 . The time constant for V O 2 phase II ( p ) was significantly slowed in both pre and postmenopausal women with T2D compared with healthy counter-parts ( Table 3 ). The rest of the parameters were not affected by T2D or menopausal status.
Cardiovascular Responses
Cardiovascular responses at rest and during cycling exercise are shown in Fig. 2 and their gains relative to workload at 30 s and 240 s are shown in Table 4 . Absolute CO responses were significantly lower in both groups of T2D compared with controls, while absolute HR responses were significantly lower only in premenopausal women with T2D than controls but not among postmenopausal women (Fig. 2) . However, when the change in absolute workload was taken into account the gains in CO, HR, and SV at 240 s were significantly larger in both groups with T2D ( Table 4 ). The absolute changes in a-vO 2 or their gains were not significantly affected by T2D. The relative change in CO from baseline (%⌬CO) was not significantly affected by diabetes (data not shown).
DISCUSSION
To our knowledge, the present study is the first to compare effects of T2D on peak exercise performance and V O 2 kinetics in pre-and postmenopausal women. Importantly, participants with T2D had similar diabetes severity and all participants were younger than 60 yr. The main findings of the present study were that peak V O 2 and peak power output were significantly reduced and V O 2 kinetics significantly slowed in preand postmenopausal women with T2D compared with their respective healthy controls and that the magnitude of these impairments was not affected by menopausal status. In addition, while the absolute responses of CO during submaximal exercise were lower in women with T2D, when taking into account the changes in absolute workload, the gains of CO were larger in both groups with T2D compared with controls suggesting that the observed impairments in V O 2 kinetics during exercise are not likely due to abnormal CO responses.
Maximum or "peak" V O 2 levels have generally been reported as being reduced in people with T2D compared with age-and sex-matched healthy controls by an average of 12-15% (21, 32, 33, 36, 38) , and this is of particular importance because low peak pulmonary oxygen uptake is associated with an increased risk of cardiovascular morbidity and premature cardiovascular mortality (2) . Whether these T2D-induced impairments in peak V O 2 are sex specific is unclear, with some investigators showing significantly larger impairments in peak V O 2 (ml·kg Ϫ1 ·min Ϫ1 ) in young premenopausal women vs. age-similar men (36) while others reporting similar peak V O 2 (ml·kg Ϫ1 ·min Ϫ1 and l/min) impairments between older postmenopausal women and age-matched men (33) (see Introduction). Thus, to further explore the possibility that the menopausal status of women would explain the contrasting findings of these two recent studies, we hypothesized that T2D would impair peak V O 2 to a larger extent in pre-compared with post-menopausal women, due at least in part to a larger relative influence of menopause in healthy women than women with T2D, given that estrogen regulates nitric oxide synthase, which improves endothelial function and tissue perfusion (45) . When interpreting normalized peak V O 2 data (ml·kg Ϫ1 ·min Ϫ1 ) in the present study the magnitude of the T2D-induced reduction was numerically larger in premenopausal women (25%) than in postmenopausal women (8%) (diabetes status ϫ menopausal status interaction, P ϭ 0.11). However, because of the bias introduced by consistently higher body weights (and BMI) of participants with T2D compared with control subjects in the literature, peak V O 2 values should be expressed in liters per minute rather than normalized to body weight (10) . When the absolute peak V O 2 values were analyzed, contrary to our main hypothesis, there were no differences in the magnitude of the T2D-induced impairments between pre-(ϳ13%) and postmenopausal (ϳ9%) women (diabetes status ϫ menopausal status interaction, P ϭ 0.57), suggesting that menopausal status does not affect the extent to which T2D impairs peak exercise responses in women. Despite this it is still worth noting that there was a tendency for a menopausal effect on absolute peak V O 2 (main effect ϭ menopausal status, P ϭ 0.11) which was ϳ11% lower in healthy post-than premenopausal women whereas it was ϳ6% lower among T2D patients. However, this lack of significant reduction due to menopause in our healthy participants is also in contrast with our secondary hypothesis, and it is somewhat surprising given that natural menopause has been shown to significantly reduce exercise tolerance and peak V O 2 by 17-25% in healthy sedentary women relative to premenopausal women of the same age (20, 23, 24) .
Reasons for the different findings between the present study and the previous studies examining the effect of menopause on peak V O 2 (20, 23, 24) are not clear but may be related to differences in participants' characteristics. For instance, in these previous studies, both the pre-and postmenopausal groups were of similar age (mean age ϭ 49 vs. 51 yr, respectively), the onset age of menopause occurred within 1 (24) and 3 yr (23) of the start of the studies, and most participants had a BMI of Ͻ25 kg/m 2 . The latter one can be particularly important because in the present study women had higher BMIs, which have been suggested to have differential effects on circulating endogenous estrogen levels according to menopausal status (35) . For instance, in postmenopausal women, estrogen is mainly synthesized by adipose tissue and as women with higher BMIs have larger adipose stores this may result in higher circulating levels of estrogen. On the other hand, despite premenopausal women having higher levels than after menopause, estrogen derives mostly from ovarian synthesis, and because overweight or obese premenopausal women are more likely to have anovulatory cycles and a greater clearance rate of estrogen by the liver compared with normal-weight women, this could lead to lower levels of circulating estrogen (35) . Since menopausal status in the present study was assessed by self-report without accompanying analysis of hormone levels and the participants' onset age of menopause was not known it is also possible that discrepancies between studies are due to differences in the time course of menopausal onset and duration because emerging evidence indicates that these factors affect cardiovascular parameters (30) . Furthermore, in contrast to the above-mentioned studies (23, 24) our study groups were not matched by age (i.e., postmenopausal women were ϳ12 yr older than premenopausal women), so, it appears that neither age nor female hormonal differences were sufficiently powerful to affect the magnitude of the diabetes-induced impairments in exercise performance.
In addition to examining the maximum responses of pulmonary V O 2 , the present study also measured the V O 2 dynamic responses during submaximal exercise, i.e., the rate of adjustment of oxygen uptake to steady-state exercise. The time constant for V O 2 phase II ( p ) was significantly slowed in both pre-and postmenopausal women with T2D compared with their healthy counterparts, a finding that is consistent with most (6, 22, 33, 38) but not all (36, 47) previous studies examining men and women with T2D of different ages. Relevant to our study is the recent work by Regensteiner et al. (36) who reported that V O 2 kinetics were not slowed due to T2D in younger premenopausal women nor in age-similar men although nonsignificant tendencies were apparent among the groups of men (main effect ϭ diabetes status, P Ͻ 0.1) (36) . The reason for the differences between the present findings and those of Regensteiner et al. (36) is uncertain but it may be explained by their premenopausal patients being in a less advanced stage of the disease (40% were on diabetic medication) than the premenopausal patients in our study (70% were on diabetic medication).
Similarly to what was observed with the "peak" V O 2 responses, in the present study the extent to which p was impaired due to T2D was similar between premenopausal and postmenopausal women, a finding that suggests a lack of an effect of menopausal status on these responses in nondiabetic healthy participants. An explanation for this finding is difficult because studies of V O 2 kinetics in postmenopausal women are limited and, to our knowledge, no studies have specifically examined the effects of menopausal status on this parameter. The most relevant published study in this regard is by Stathokostas et al. (43) who compared the effects of a short aerobic exercise training program on V O 2 kinetics responses in postmenopausal women taking hormonal replacement therapy (HRT) with those not taking HRT. At baseline, authors reported longer p values during submaximal exercise in postmenopausal women taking HRT (ϳ48 s) and those not on HRT (ϳ45 s) than in the present study (ϳ33 s). In addition, two more studies investigating the effects of aging (27) and training status (8) on V O 2 kinetics responses have also examined healthy older women. In the study by Murias et al. (27) older healthy women had a p of ϳ55 s and in the study by Dogra et al. (8) it was ϳ57 s; however, it is important to acknowledge that in both these studies participants were aged 60 yr or above. Indeed, even though the mean age of participants in the study by Stathokostas et al. (43) was ϳ57 yr it is likely that they also included older participants (Ͼ60 yr) which possibly influenced the longer responses in p of their postmenopausal participants. Nevertheless it is still noteworthy that in the present study the relative difference in p between pre-and postmenopausal healthy controls (ϳ12%) was substantially greater than between pre-and postmenopausal groups with T2D (approximately Ϫ3%).
To explore the mechanistic basis of any menopausal statusand T2D-specific effects in V O 2 kinetics cardiac output was measured during submaximal cycling exercise. Absolute CO responses were significantly lower in both groups of T2D compared with healthy controls; however, CO is a function of power output and V O 2 , and it is therefore important to normalize it to either of these variables. For this reason, we calculated the gains in CO, HR, and SV taking into account the change in absolute workload which revealed significantly larger gains in both groups with T2D compared with healthy controls. These findings are in agreement with previous studies using noninvasive (4, 22, 32, 33) as well as invasive methods to measure CO (39) and suggest that cardiac responses do not contribute to the observed diabetes-induced impairments in the dynamic response of V O 2 , at least in patients with uncomplicated T2D. The latter study, even if it explored a graded exercise test, is particularly important since despite not observing differences in CO, HR, and SV, Regensteiner and colleagues (39) reported that pulmonary capillary wedge pressure was abnormally increased during graded exercise in recently diagnosed type 2 diabetic patients, a condition that is thought to precede the development of overt cardiac dysfunction (16) .
Even if the mechanisms for these V O 2 kinetics impairments in T2D are not well understood, maldistribution and/or slowing of blood flow/vascular conductance during exercise are likely to be involved. For instance, the dynamic responses of limb vascular conductance during isolated calf exercise at a highintensity (70% maximal voluntary contraction) is slowed in T2D (14, 21) and the peak hyperemic response following a graded exercise of the same muscles is reduced (14) . Similarly, these diabetes-induced reductions in blood flow have also been observed during low-intensity knee extension exercise (18) and supine moderate-intensity cycling exercise (15) . Microvascular blood flow responses, estimated from near-infrared spectros- (32) } have been reported in men with T2D which are in line with the direction, although nonsignificant, of a-vO 2 responses observed in the present study. The observation in the present study that the responses to forearm reactive hyperemia were similar in people with T2D and nondiabetic controls is consistent with some (48), but not all (36) , previous studies and suggests that the functional integrity of the vascular smooth muscle is not impaired in uncomplicated T2D. Although more studies exploring the dynamic responses of muscle hyperemia during whole body exercise are needed to elucidate this, it is likely that local vascular constraints contribute to impair dynamic and peak V O 2 responses in Type 2 diabetes. Indeed it is important to acknowledge that recent studies using the priming exercise model in young healthy people both under hypoxic conditions (41) and in normoxia (28, 29) have suggested that, at least when V O 2 p is larger than ϳ20 s, a mismatch between O 2 delivery to and O 2 utilization from the active tissues is present. This is important as it reinforces that local muscle O 2 delivery has a determining role in the dynamic adjustment of oxidative phosphorylation even in healthy populations.
Limitations
The small sample size, the assessment of menopausal status by only self-report, and absence of the menopausal onset age as well as participants age being restrained in both pre-(range 30 -46 yr) and postmenopausal (range 46 -59 yr) women are limitations of the present study. Nevertheless, the latter was important to exclude a potential confounding effect of age. It is also important to acknowledge that there were a higher number of participants on statins in the postmenopausal group with T2D compared with the other three groups and that the use of the V-slope approach on the graded step test while employing a small number of relatively long (i.e., 3 min) increments may have contributed to the overestimation of VT in 9 of the participants. Moreover, V O 2 and CO responses not being measured simultaneously (the rebreathing system employed does not calculate V O 2 responses while measuring CO data), functional gains of cardiovascular variables being calculated from values corresponding to static rest (instead of baseline), and cardiac output being assessed at only two time points are also limitations.
Perspectives and Significance
Pre-and postmenopausal women with T2D exhibited a significant reduction of peak V O 2 and slowing of V O 2 kinetics, and these impairments in V O 2 kinetics were not likely due to abnormalities in CO responses. Moreover, the magnitude of these impairments was not affected by menopause (i.e., by differences in female hormones) or ageing. Thus, while the mechanistic bases of the exercise impairments observed in T2D remain to be determined, these results suggest that the effect of T2D on peak V O 2 during maximal exercise and V O 2 kinetics responses during moderate-intensity exercise are not affected by menopausal status in participants of Ͻ60 yr. Future studies should examine larger sample sizes, assess cardiac responses more frequently, and take into consideration the onset age and duration of menopause. 
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